Efficacy of RTS,S malaria vaccines: individual-participant pooled analysis of phase 2 data  by Bejon, Philip et al.
www.thelancet.com/infection   Vol 13   April 2013 319
Articles
Eﬃ  cacy of RTS,S malaria vaccines: individual-participant 
pooled analysis of phase 2 data
Philip Bejon, Michael T White, Ally Olotu, Kalifa Bojang, John P A Lusingu, Nahya Salim, Nekoye N Otsyula, Selidji T Agnandji, Kwaku Poku Asante, 
Seth Owusu-Agyei, Salim Abdulla, Azra C Ghani
Summary
Background The eﬃ  cacy of RTS,S/AS01 as a vaccine for malaria is being tested in a phase 3 clinical trial. Early results 
show signiﬁ cant, albeit partial, protection against clinical malaria and severe malaria. To ascertain variations in 
vaccine eﬃ  cacy according to covariates such as transmission intensity, choice of adjuvant, age at vaccination, and 
bednet use, we did an individual-participant pooled analysis of phase 2 clinical data.
Methods We analysed data from 11 diﬀ erent sites in Africa, including 4453 participants. We measured heterogeneity 
in vaccine eﬃ  cacy by estimating the interactions between covariates and vaccination in pooled multivariable 
Cox regression and Poisson regression analyses. Endpoints for measurement of vaccine eﬃ  cacy were infection, 
clinical malaria, severe malaria, and death. We deﬁ ned transmission intensity levels according to the estimated local 
parasite prevalence in children aged 2–10 years (PrP2–10), ranging from 5% to 80%. Choice of adjuvant was either AS01 
or AS02.
Findings Vaccine eﬃ  cacy against all episodes of clinical malaria varied by transmission intensity (p=0·001). At low 
transmission (PrP2–10 10%) vaccine eﬃ  cacy was 60% (95% CI 54 to 67), at moderate transmission (PrP2–10 20%) it was 
41% (21 to 57), and at high transmission (PrP2–10 70%) the eﬃ  cacy was 4% (–10 to 22). Vaccine eﬃ  cacy also varied by 
adjuvant choice (p<0·0001)—eg, at low transmission (PrP2–10 10%), eﬃ  cacy varied from 60% (95% CI 54 to 67) for AS01 
to 47% (14 to 75) for AS02. Variations in eﬃ  cacy by age at vaccination were of borderline signiﬁ cance (p=0·038), and 
bednet use and sex were not signiﬁ cant covariates. Vaccine eﬃ  cacy (pooled across adjuvant choice and transmission 
intensity) varied signiﬁ cantly (p<0·0001) according to time since vaccination, from 36% eﬃ  cacy (95% CI 24 to 45) at 
time of vaccination to 0% (–38 to 38) after 3 years.
Interpretation Vaccine eﬃ  cacy against clinical disease was of limited duration and was not detectable 3 years after 
vaccination. Furthermore, eﬃ  cacy fell with increasing transmission intensity. Outcomes after vaccination cannot be 
gauged accurately on the basis of one pooled eﬃ  cacy ﬁ gure. However, predictions of public-health outcomes of 
vaccination will need to take account of variations in eﬃ  cacy by transmission intensity and by time since vaccination.
Funding Medical Research Council (UK); Bill & Melinda Gates Foundation Vaccine Modelling Initiative; 
Wellcome Trust.
Introduction
The increasing application of interventions for malaria 
control over the past 10 years has been linked to 
reductions in morbidity and mortality associated with 
malaria infection.1,2 A vaccine for malaria could have an 
important role in further reduction of the burden of 
disease. The candidate malaria vaccine RTS,S/AS01 is 
now in phase 3 clinical trials, for which preliminary data 
for the ﬁ rst 12 months of follow-up are available.3 Eﬃ  cacy 
against clinical malaria was 55·8% (97·5% CI 50·6–60·4) 
among children age 5–17 months. Combined eﬃ  cacy 
against severe malaria for children aged 5–17 months 
and 6–12 weeks was 34·8% (95% CI 16·2–49·2).
RTS,S protects at pre-erythrocytic stages of the 
parasite’s lifecycle. It is partly eﬀ ective and has been 
described as a leaky vaccine4—ie, no individual is 
protected consistently against every episode of exposure, 
but the risk of acquiring infection after any single episode 
of exposure is reduced. In ﬁ eld trials, RTS,S has been 
given with either of two diﬀ erent adjuvant systems: AS01 
or AS02. Although RTS,S/AS01 seems to be more 
immunogenic than RTS,S/AS02, eﬃ  cacy trials of RTS,S/
AS01 and RTS,S/AS02 have not resulted in deﬁ nitively 
powered comparisons.5,6 Furthermore, the variation in 
vaccine eﬃ  cacy over time remains unknown, with 
conﬂ icting evidence from individual trials.
Vaccine eﬃ  cacies are usually summarised with point 
estimates. However, if vaccine eﬃ  cacy is heterogeneous 
by subgroups within the population, this eﬃ  cacy ﬁ gure 
will be a mean of the vaccine eﬃ  cacy in the various 
subgroups, weighted according to the proportion of the 
population.7 For instance, if vaccine eﬃ  cacy is higher in 
older children then the overall eﬃ  cacy in a particular trial 
will depend on the proportion of older children to 
younger children that are vaccinated.
Analysis of phase 2b data to date shows variations in 
measured eﬃ  cacy between trials.6,8–16 These diﬀ erences 
might be attributable to the vaccine formulation, 
intensity of transmission, length of follow-up, or age-
range of participants. To ascertain which covariates are 
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associated with variations in vaccine eﬃ  cacy, we did a 
pooled analysis of data from phase 2b trials.
Methods
Data collection
We identiﬁ ed phase 2b trials6,8–16 of RTS,S from the 
GlaxoSmithKline Biologicals registry of trials (data on 
ﬁ le), and raw data were provided by GSK Biologicals to 
three academic investigators (PB, MTW, and ACG). One 
of us (PB) checked data for completeness by comparing 
data summaries with the primary publications; all 
investigators analysed the data. Characteristics of the 
trials, done at 11 sites in total (from six countries), are 
summarised in table 1.
In the identiﬁ ed trials, healthy adults or children were 
recruited after clinical and laboratory screening to 
exclude participants with clinically signiﬁ cant disease. 
Five trials of children or adults used active case detection 
for Plasmodium falciparum infection (ACDi),6,8–11 one used 
active case detection for clinical malaria (ACDc),12 and 
two used passive case detection (PCD) for clinical 
malaria10,13 (one trial used both ACDi and PCD). Trials 
using ACDi and ACDc included assessment of 
participants who presented with acute illness between 
scheduled visits, which is usually referred to as PCD in 
protocols. For simplicity, in our analysis here we use 
ACDi to refer to the combination of ACDi and PCD, 
ACDc to refer to combined ACDc and PCD, and PCD to 
refer to exclusive use of PCD. ACDi was done after 
antimalarial treatment during the vaccination course and 
was then monitored with regular ﬁ nger-prick blood 
smears. Deaths and severe malaria episodes were 
monitored in all ﬁ ve trials in which children were 
enrolled.
Procedures
We used four primary endpoints in our analysis: 
infection, clinical malaria, severe malaria, and death. In 
the trials we identiﬁ ed, infection was deﬁ ned as any 
detectable P falciparum parasitaemia, with or without a 
measured fever. We deﬁ ned clinical malaria as the 
presence of 2500 or more P falciparum parasites per μL of 
blood in association with reported or measured fever 
(≥37·5°C).17,18 We deemed clinical malaria episodes 
occurring within 28 days of a previous episode to be part 
of the same episode. We did not censor time of 
monitoring according to antimalarial drug use or 
reported absences from the study area.
We analysed episodes of infection identiﬁ ed by ACDi 
as one dataset. We combined clinical malaria episodes 
identiﬁ ed by ACDc and PCD and analysed these as a 
second dataset. ACDc and PCD were included in the 
initial study protocols, except for one trial,13 in which 
the eﬃ  cacy assessment was included after a protocol 
amendment as an exploratory objective, for which some 
data were extracted retrospectively.
We identiﬁ ed episodes of severe malaria from safety 
data reporting. Criteria for severe malaria were derived 
from the WHO deﬁ nition19 and were applied by the 
clinical investigators at every site, comprising asexual 
P falciparum parasitaemia, no alternative (or more 
probable) cause of illness, and either severe malaria 
Patients 
(n)
Active vaccine Control vaccine Surveillance Median age (IQR) Local 
parasite 
prevalence 
(%)*
Bednet use Eﬃ  cacy 
(95% CI)
Gambia8 250 RTS,S/AS02A Rabies ACDi, weekly blood ﬁ lms 24 years (19–34) 70 13% 34% (8 to 53)
Mozambique 
(cohort 1)10,14,16
1589 RTS,S/AS02A Hepatitis B or pneumococcal 
conjugate/Haemophilus 
inﬂ uenzae type B
PCD 35 months (24–48) 40 4·5% 30% (11 to 45)
Mozambique 
(cohort 2)10,14,16
411 RTS,S/AS02A Hepatitis B or pneumococcal 
conjugate/H inﬂ uenzae type B
ACDi, blood ﬁ lms every 
2 weeks for 9 months 
then passive only
36 months (24–45) 70 22% 45% (31 to 56)
Bagamoyo, Tanzania13 209 RTS,S/AS01E Placebo PCD 1·8 months (1·7–1·9) 30 Not recorded 53% (26 to 70)
Gabon13 215 RTS,S/AS01E Placebo PCD 1·5 months (1·4–1·7) 5 Not recorded 53% (26 to 70)
Ghana13 81 RTS,S/AS01E Placebo PCD 1·6 months (1·5–1·8) 80 Not recorded 53% (26 to 70)
Kiliﬁ , Kenya12,15 447 RTS,S/AS01E Rabies ACDc, weekly visits 11 months (8–14) 35 59% 53% (28 to 69)
Korogwe, Tanzania12,15 447 RTS,S/AS01E Rabies ACDc, weekly visits 12 months (9–15) 15 52% 53% (28 to 69)
Kisumu, Kenya6 250 RTS,S/AS02A and 
RTS,S/AS01B
Rabies ACDi, weekly blood ﬁ lms 25 years (21–29) 60 0% 30% (–15 to 57)
Mozambique (infants)9 214 RTS,S/AS02D Hepatitis B ACDi, blood ﬁ lms every 
2 weeks
1·8 months (1·8–2·1) 45 100%† 66% (43 to 80)
Bagamoyo, Tanzania 
(infants)11
340 RTS,S/AS02D Hepatitis B ACDi, blood ﬁ lms every 
2 weeks
1·9 months (1·8–2) 30 100%† 65% (21 to 85)
ACDi=active case detection for infection. ACDc=active case detection for clinical malaria. PCD=passive case detection for clinical malaria. *Age-corrected parasite prevalence data taken from the Malaria Atlas 
Project. †Bednets were distributed to every child taking part in these trials and 100% use is assumed. 
Table 1: Characteristics of diﬀ erent sites
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anaemia (haemoglobin <50 g/L), cerebral malaria 
(Blantyre coma score <2), or another symptom (multiple 
generalised convulsions in 24 h, prostration, hypo-
glycaemia [<2·2 mmol/L], acidosis, or shock).
Our primary analysis was vaccine eﬃ  cacy, which was 
assessed per-protocol. Hence, cohorts monitored for 
infection or clinical malaria included all participants who 
had received three doses of vaccine, from 2 weeks after 
the third dose. We did not judge adults at risk of severe 
disease or death from malaria. Analysis of severe malaria 
or death was based on intention to treat and included all 
children who received at least one dose of vaccine, from 
the time of the ﬁ rst vaccination.
In Mozambique,10,14,16 one cohort (cohort 2) ﬁ rst 
underwent ACDi in a double-blind phase then sub-
sequently underwent PCD for clinical malaria in a single-
blind phase. We included data from the double-blind 
phase in the ACDi dataset and those from the single-
blind phase in the clinical malaria dataset, taking the 
start of the single-blind phase as the initial time of 
monitoring for clinical malaria.
We recorded the following covariates across the seven 
trials: sex, age at the time of vaccination, country, bednet 
use, adjuvant used (ie, AS01 vs AS02), and clinical disease 
surveillance method at the site level (ie, ACDc vs PCD 
only). To ascertain transmission intensity, we used 
estimates from the Malaria Atlas Project (MAP) for 
prevalence of asymptomatic parasitaemia in children 
aged 2–10 years in 2007 (PrP2–10),20 identiﬁ ed with the 
geopositioning coordinates of the trial sites. We refer to 
this measure here as the local parasite prevalence.
Statistical analysis
We summarised unadjusted vaccine eﬃ  cacy for the 
four endpoints of infection, clinical malaria, severe 
malaria, and death with Kaplan-Meier curves and eﬃ  cacy 
estimates with unadjusted Cox proportional-hazard 
models for ﬁ rst or only event. To analyse ACDi and 
combined ACDc and PCD, we assessed the eﬀ ect 
of covariates with adjusted Cox proportional-hazard 
models. We analysed multiple episodes of clinical 
malaria with Poisson regression, adjusting for the time 
of follow-up as an oﬀ set variable, implemented as one 
observation per participant.
Rather than present subgroup analyses according to 
strata (which would be necessarily narrow and be 
typically confounded by other important covariates), we 
pooled individual participant data and estimated the 
For more on the Malaria Atlas 
Project see http://www.map.ox.
ac.uk/
 Figure 1: Kaplan-Meier survival plots, according to endpoint
(A) Active case detection for infection. (B) First episode of clinical malaria on active or passive case detection for clinical malaria. (C) Severe malaria. (D) Death.
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linear and non-linear eﬀ ect of covariates in the data and 
the interactions of these covariates with vaccine eﬃ  cacy. 
We used these empirically observed functions to 
estimate eﬃ  cacy in subgroups by multiplying the ﬁ xed 
eﬀ ect of vaccination (ie, the estimate of the eﬀ ect of 
vaccination among those with the baseline value of the 
covariate) by the interaction term (ie, the estimate of 
how vaccine eﬃ  cacy varies for each diﬀ erent level of the 
covariate). We added variances and the covariance matrix 
to calculate SEs. All covariates were included in an initial 
model, and we excluded covariates or interaction terms 
with p greater than 0·05 to produce a ﬁ nal model. To 
examine the possibility that analyses of clinical malaria 
risk were biased by unequal durations of follow-up in 
some subgroups, we did an additional analysis restricted 
to 1 year of follow-up.
We calculated vaccine eﬃ  cacy as either 1 minus the 
hazard ratio or 1 minus the incidence rate ratio. We 
modelled the non-linear eﬀ ects of age at vaccination and 
local parasite prevalence as multiple fractional poly-
nomials, according to the method of Royston and 
colleagues.21 We ﬁ tted changes in vaccine eﬃ  cacy over 
time as an interaction between time and vaccination 
status in Cox regression models, using the Anderson Gill 
modiﬁ cation,22 with clustering by individual to include 
multiple episodes.
We examined parametric survival models to ﬁ t a 
γ distribution to the unmeasured heterogeneity in 
exposure. We used a Gompertz survival distribution for 
parametric models, since this method ﬁ tted the data 
better than the alternatives (exponential, log normal, or 
Weibull) and gave hazard ratios for vaccination that 
Figure 2: Adjusted forest plots for estimates of vaccine eﬃ  cacy
Reference is RTS,S/AS01, young children (age 12 months), female sex, no bednet use, and low transmission (20% parasite prevalence). (A) First episode of clinical 
malaria (Cox regression). (B) Multiple episodes of clinical malaria (Poisson regression).
Eﬃcacy (95% CI)A
Reference
AS02
Age 3 years at vaccination
10% parasitic prevalence
20% parasitic prevalence
70% parasitic prevalence
Bednet use
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Passive case detection
37% (23 to 48)
18% (–47 to 54)
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37% (23 to 48)
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0396378 –65 –65
Eﬃcacy (95% CI)B
41% (21 to 57)
37% (–3 to 61)
58% (46 to 67)
60% (54 to 67)
41% (21 to 57)
  4% (–10 to 22)
50% (20 to 68)
50% (23 to 67)
68% (47 to 80)
Vaccine eﬃcacy (%)
0396378
Cox regression for infection 
(ACDi)
Cox regression for ﬁ rst episode 
of clinical malaria (ACDc/PCD)
Poisson regression for all episodes of 
clinical malaria (ACDc/PCD)
Hazard ratio (95% CI) p Hazard ratio (95% CI) p Incidence rate ratio (95% CI) p
RTS,S vaccination 0·78 (0·70–0·88) 0·001 0·63 (0·52–0·77) <0·0001 0·59 (0·43–0·79) 0·001
Sex (male vs female) 1·27 (1·04–1·54) 0·017 1·05 (0·90–1·22) 0·54† 1·05 (0·95–1·15) 0·38†
Sex*RTS,S 1·21 (0·91–1·61) 0·18 0·92 (0·72–1·37) 0·45† 0·99 (0·86–1·14) 0·87†
AS02 trial‡ ·· ·· 1·21 (0·84–1·74) 0·31 1·17 (0·88–1·55) 0·27
AS02 trial*RTS,S ·· ·· 1·58 (1·01–2·47) 0·046 2·30 (1·54–3·44) <0·0001
Age (3 years vs 5 months) 1·00 (0·99–1·01) 0·81 0·80 (0·76–0·85) <0·0001 0·79 (0·75–0·84)§ <0·0001
Age*RTS,S 1·00 (0·99–1·01) 0·89† 1·03 (0·92–1·16) 0·62† 0·92 (0·85–0·99)§ 0·038
Parasite prevalence (50% vs 10%)¶ 21·2 (10·3–44) <0·0001 2·71 (1·54–4·75) 0·001 3·42 (2·35–4·97)§ <0·0001
Parasite prevalence*RTS,S 2·1 (0·72–6·3) 0·17† 2·65 (1·21–5·80) 0·015 2·47 (1·45–4·21)§ 0·001
Bednet 0·88 (0·65–1·17) 0·37† 0·80 (0·63–1·01) 0·065† 1·08 (0·94–1·24) 0·26†
Bednet*RTS,S 1·07 (0·71–1·62) 0·74† 1·35 (0·96–1·91) 0·064† 0·93 (0·76–1·14) 0·50†
Passive case detection ·· ·· 0·99 (0·71–1·39) 0·96 0·66 (0·51–0·84) 0·001
Passive case detection*RTS,S ·· ·· 0·61 (0·38–0·97) 0·039 0·49 (0·34–0·71) <0·0001
*RTS,S denotes the interaction between RTS,S vaccination and the preceeding covariate. A value of 1 indicates no interaction, with RTS,S having the same eﬀ ect irrespective 
of variation in the covariate. A value >1 indicates RTS,S is less eﬀ ective with the covariate, and a value <1 indicates RTS,S is more eﬀ ective with the covariate. †Data were 
non-signiﬁ cant and therefore were excluded in the ﬁ nal model. ‡Participants who were randomised in trials of RTS,S/AS02 versus control vaccination. §For Cox regression, 
non-linear eﬀ ects did not diﬀ er from linear eﬀ ects (p=0·38 and p=0·21, respectively), and hazard ratios refer to linear eﬀ ects. ¶Standardised local parasite prevalence in the 
community in children aged 2–10 years in 2007, derived from the Malaria Atlas Project. Background parasite prevalence and age have been scaled so that the ﬁ xed eﬀ ect of 
RTS,S is for 20% parasite prevalence at age 1 year. 
Table 2: Risk of infection or clinical malaria according to covariate
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were nearly identical to those estimated using 
Cox proportional-hazards.
Role of the funding source
We did this pooled analysis after a call for proposals 
initiated and facilitated by GlaxoSmithKline Biologicals. 
Employees of GSK Biologicals were investigators on the 
original phase 2 studies and were authors on the 
primary reports. Employees of GSK Biologicals 
reviewed the analysis plan and commented on early 
drafts of the pooled analysis, but were not required to 
give ﬁ nal approval of the manuscript. The corresponding 
author had full access to all the data in the study and 
had ﬁ nal responsibility for the decision to submit for 
publication.
Results
We analysed pooled data for 4453 participants in seven 
trials (table 1). 1376 participants received all three vac-
cinations, were given curative antimalarial treatment, 
and underwent ACDi. 3184 participants received all three 
vaccinations and were monitored for episodes of clinical 
malaria, either by ACDc or PCD. 465 adults received one 
or more vaccination; these data were excluded from the 
analysis for severe malaria or death. 3988 children (ie, 
younger than 6 years at vaccination) received one or 
more vaccination and were included in intention-to-treat 
analyses for severe malaria or death.
The survival functions for the four endpoints are 
shown in ﬁ gure 1. Unadjusted eﬃ  cacy by ACDi was 33% 
(95% CI 23–42; p<0·0001). Vaccine eﬃ  cacy by ACDi did 
not vary signiﬁ cantly with respect to the covariates tested 
(table 2). Unadjusted eﬃ  cacy against clinical malaria by 
ACDc and PCD was 25% (95% CI 16–33; p<0·0001) for 
ﬁ rst episodes and 19% (12–25; p<0·0001) for all episodes. 
However, signiﬁ cant interactions were noted between 
vaccine eﬃ  cacy and other covariates (table 2).
On Cox regression, vaccine eﬃ  cacy against ﬁ rst 
episodes of clinical malaria was 37% (95% CI 23 to 48) 
with a local parasite prevalence of 20% (moderate 
transmission; table 2). However, estimated eﬃ  cacies 
were 48% (41 to 50) at a local parasite prevalence of 10% 
(low transmission) and 7% (–55 to 44) at a local parasite 
prevalence of 70% (high transmission; ﬁ gure 2). Vaccine 
eﬃ  cacy against all episodes of clinical malaria on Poisson 
regression, allowing for the non-linear eﬀ ects shown in 
ﬁ gure 3, was 41% (95% CI 21 to 57) at a local parasite 
prevalence of 20% (table 2). Estimated vaccine eﬃ  cacies 
were 60% (54 to 67) at a local parasite preva lence of 10% 
and 4% (–10 to 22) at a local parasite prevalence of 70% 
(ﬁ gure 2). Vaccine eﬃ  cacy also varied by adjuvant 
choice—eg, at low transmission (PrP2–10 10%) eﬃ  cacy 
varied from 60% (95% CI 54 to 67) for AS01 versus 47% 
(14 to 75) for AS02; however, eﬃ  cacy did not diﬀ er by 
bednet use or by gender. Vaccine eﬃ  cacy varied sig-
niﬁ cantly by age for all episodes of clinical malaria 
Figure 3: Risk of clinical malaria, according to covariate
(A) Incidence of malaria, by local parasite prevalence. (B) Incidence of malaria, by age (months) at vaccination. (C) Vaccine eﬃ  cacy, by local parasite prevalence. 
(D) Vaccine eﬃ  cacy, by age (months) at vaccination. p<0·0001 for non-linear trends shown for multiple fractional polynomials compared with linear trends. Solid line 
represents the point estimate for eﬃ  cacy, dotted lines represent the 95% CI.
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(p=0·038), but not for ﬁ rst episodes of clinical malaria 
(p=0·62; table 2).
Repeating the analysis but restricting follow-up to the 
ﬁ rst year after vaccination resulted in a similar pattern of 
results to those reported in table 2, albeit with wider CIs 
and more marginal signiﬁ cance. For the interaction with 
adjuvant, the hazard ratio was 1·46 (95% CI 1·00–2·12, 
p=0·049) and the incidence rate ratio was 2·22 
(1·35–3·64). For the interaction with local parasite 
prevalence, the hazard ratio was 1·51 (0·61–3·72, p=0·38) 
and the incidence rate ratio was 1·89 (0·93–3·8, p=0·078).
Unadjusted eﬃ  cacy against severe malaria was 37% 
(95% CI 6 to 58, p=0·023); data were from 39 children 
with severe malaria from a total of 2080 RTS,S vaccinated 
people, versus 58 children with severe malaria from a total 
of 1908 controls. Eﬃ  cacy against death was 48% (–8 to 75, 
p=0·081); 11 deaths occurred in the 2080 people receiving 
vaccine and 19 deaths happened among the 1908 controls. 
We judged the frequency of severe malaria and death to be 
too low to justify further multivariable analysis.
The survival plot of time to infection during ACDi by 
vaccination status shows convergence after the initial 
divergence (ﬁ gure 1A), and the plot of time to clinical 
malaria by ACDc and PCD shows a gradual slowing in 
the rate of divergence (ﬁ gure 1B). An interaction between 
eﬃ  cacy and time gave similar goodness of ﬁ t (judged by 
Akaike’s information criterion) for various powers of 
time (2, –1, –2, 0·5, 0·25) and linear and log functions. 
We therefore selected a linear ﬁ t for simplicity and to 
make interpretation of the interaction terms more 
intuitive (ﬁ gure 4).
In unadjusted analysis of ACDi, eﬃ  cacy seems to wane 
rapidly (ﬁ gure 4A), but after adjustment for local parasite 
prevalence and for a γ-distributed shared frailty ( =0·96, 
p<0·0001, in dicating that signiﬁ cant evidence exists for 
Figure 4: Vaccine eﬃ  cacy against time
(A) Infection on active case detection. (B) Infection on active case detection after adjustment for known variation in exposure to malaria (using local parasite 
prevalence as a ﬁ xed eﬀ ect) and unknown variation in exposure (ﬁ tting a shared γ-distributed frailty). (C) First episodes of clinical malaria on active or passive case 
detection. (D) Multiple episodes of clinical malaria on active or passive case detection. (E) Multiple episodes of clinical malaria after adjustment for known variation in 
exposure to malaria (using local parasite prevalence as a ﬁ xed eﬀ ect) and unknown variation in exposure (ﬁ tting a shared γ-distributed frailty). Solid line represents 
the point estimate for eﬃ  cacy, dotted lines represent the 95% CI.
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pronounced heterogeneity of risk), the eﬀ ect of 
vaccination did not vary by much over time (ﬁ gure 4B, 
table 3). In unadjusted and adjusted analyses of ACDc 
and PCD, including single and multiple clinical episodes, 
the estimated vaccine eﬃ  cacy fell over time, from 36% 
eﬃ  cacy (95% CI 24 to 45) at time of vaccination to 0% 
(95% CI –38 to 38) at 3 years (ﬁ gures 4C–E).
We tested for heterogeneity in the rate of declining 
vaccine eﬃ  cacy against clinical malaria by estimating the 
three-way interactions between time (in years), vaccination, 
and every covariate in turn. None of these three-way 
interaction terms were signiﬁ cant at the 5% level (AS02 vs 
AS01, hazard ratio 0·94, 95% CI 0·82–1·09, p=0·46; local 
parasite prevalence hazard ratio 1·35, 0·74–2·46, p=0·33; 
age in years hazard ratio 0·97, 0·93–1·01, p=0·15).
Discussion
The ﬁ ndings of our pooled analysis show that the RTS,S 
malaria vaccine is protective against infection and 
disease. However, unadjusted eﬃ  cacy against clinical 
malaria was lower than previous estimates in children 
age 5–17 months12 and substantial heterogeneity was 
noted in eﬃ  cacy between population subgroups and over 
time. Vaccine eﬃ  cacy against clinical malaria was lowest 
at high (70%) transmission intensity, and it was reduced 
for the AS02 adjuvant compared with AS01. Weak 
variation in eﬃ  cacy was noted according to age on 
Poisson regression, which was not signiﬁ cant on Cox 
regression. Vaccine eﬃ  cacy did not vary by gender or 
bednet use. Results for eﬃ  cacy from Cox regression for 
ﬁ rst episodes and Poisson regression for all episodes 
were similar, although CIs suggested greater precision 
when all episodes were included.
A higher vaccine eﬃ  cacy with PCD versus ACDc might 
indicate bias resulting from a prophylactic eﬀ ect of 
antimalarial drugs administered for episodes of malaria 
that do not meet the case deﬁ nition. These malaria 
episodes are likely to be more common in unvaccinated 
children and hence could result in an underestimate of 
vaccine eﬃ  cacy on ACDc. However, no sites used PCD 
and ACDc alongside each other, hence there is 
confounding by site and the diﬀ erence might reﬂ ect 
other variations between sites that were not measured by 
the available covariates. To examine whether additional 
unmeasured factors that segregate by site might lead to 
varying eﬃ  cacy, we ﬁ tted a post-hoc interaction term 
between vaccination and stratiﬁ cation by site, in addition 
to the previous model (table 2). These additional 
interactions signiﬁ cantly improved model ﬁ t (p<0·0001, 
by likeli hood-ratio test), indicating that other unmeasured 
factors cause vaccine eﬃ  cacy to vary between sites.
Transmission intensity (as measured by local parasite 
prevalence in children age 2–10 years) had a non-linear 
eﬀ ect on clinical malaria incidence.23 The incidence of 
clinical malaria reached a peak in areas with a local 
parasite prevalence of 40%. This ﬁ nding could be 
accounted for by children who acquire greater immunity 
with increasing exposure, which oﬀ sets the rises in 
incidence of clinical malaria that otherwise might be 
seen at a higher local parasite prevalence.
RTS,S can be regarded as a leaky barrier to infection, 
because it protects against some infectious bites but not 
against others.24 The probability of protecting a par tici-
pant exposed to two infective bites during the course of a 
night against a subsequent episode of clinical malaria is 
half the probability of protecting a participant exposed to 
one bite. This statistic suggests that vaccine eﬃ  cacy will 
be lower at high transmission intensity, which accords 
with our observations.
We used MAP estimates of age-adjusted prevalence of 
asymptomatic malaria (PrP2–10) to gauge transmission 
intensity. These approximations were based on several 
thousand surveys in the countries where trial sites were 
located. We chose these standardised independent meas-
ures rather than within-trial factors, such as incidence of 
malaria among controls, because monitoring was not 
the same between trials. MAP estimates do not account 
for changes over time, but transmission intensity at our 
sites is likely to be stable enough over a few years for 
these data to be a reasonable approximation. Variations 
in seasonal transmission have a modest eﬀ ect on the 
relation between entomological inoculation rate and 
asymptomatic parasitaemia, but in view of the 
limitations of using data from 11 sites, we did not feel 
that more complex characterisations of transmission 
intensity were warranted.
Our ﬁ nding that vaccine eﬃ  cacy is not aﬀ ected by 
use of insecticide-treated bednets but is diminished at 
higher levels of transmission intensity might seem 
contradictory, since bednet use might be expected to 
reduce exposure and, hence, enhance vaccine eﬃ  cacy. 
However, individual use of insecticide-treated bednets 
might be only modestly protective (compared with 
greater mass eﬀ ects at reducing transmission when 
whole com munities use bednets). Furthermore use of 
insecticide-treated bednets was not distributed evenly by 
site, varying from 4·5% to 100% of children. Tests for 
variation in vaccine eﬃ  cacy by bednet use are, therefore, 
vulnerable to ecological confounding by site.
We identiﬁ ed signiﬁ cant interactions between time 
and vaccine eﬃ  cacy. We can conﬁ dently reject the null 
hypothesis that vaccine eﬃ  cacy is constant over time 
(p<0·0001), but we cannot be conﬁ dent about the shape 
of the plotted decline, which is reﬂ ected in the wide CIs 
surrounding estimates of eﬃ  cacy at later timepoints 
(ﬁ gure 4). We chose a linear interaction for simplicity of 
presentation, although power functions of time ﬁ t the 
data slightly better. Therefore, we cannot extrapolate 
beyond the data to longer durations of follow-up, since 
the shape of the line is determined by statistical 
convenience rather than biological understanding.
A fall in vaccine eﬃ  cacy over time might be attributable 
to systematic bias in estimates obtained using survival 
analysis because of heterogeneous exposure from a partly 
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eﬀ ective vaccine, as previously described.25 Com parison 
of ﬁ gure 4A with ﬁ gure 4B suggests that systematic bias 
resulting from heterogeneous exposure can account for 
the apparent waning of eﬃ  cacy in the ACDi dataset, 
rather than a genuine biological waning of eﬃ  cacy taking 
place. However, similarity between ﬁ gures 4C–E suggests 
that no clear systematic bias exists in estimates of eﬃ  cacy 
over time when using data from ACDc or PCD for clinical 
malaria. The diﬀ erence could be because ACDi was 
monitored during one trans mission season, with only 
60% of participants having an episode during this period. 
A few unexposed individuals can lead to a biased estimate 
of rapidly declining eﬃ  cacy.25 However, data for clinical 
malaria included 4 years of monitoring during many 
transmission seasons. Furthermore, individual exposure 
could vary from year to year.26 Hence, a discrete unexposed 
popu lation is less likely to exist with ACDc or PCD 
compared with ACDi. Heterogeneous exposure, 
therefore, seems to be a suﬃ  cient explanation for the 
observation that eﬃ  cacy wanes more rapidly in the ACDi 
dataset than it does in the ACDc and PCD dataset.
We report here all phase 2 data for RTS,S malaria 
vaccines (panel), including eﬃ  cacy outcomes for clinical 
malaria (ACDc and PCD) and for malaria infection 
(ACDi). Some phase 2 trials also included cross-
sectional surveys for asymptomatic parasitaemia. In the 
Mozam bique trial, substantial protection against 
asymptomatic parasitaemia was noted 45 months after 
vaccination in cohort 1,14 which is longer than would 
have been predicted by our analysis. On the other hand, 
protection against asymptomatic parasitaemia was not 
noted in Mozam bique cohort 2 at 21 months after 
vaccination. This ﬁ nding could be explained by 
diﬀ erential acquisition of blood-stage immunity 
between these two cohorts.27 Our data do not allow us to 
distinguish waning vaccine-induced immunity from 
delayed acquisition of blood-stage immunity, but 
analysis of the eﬀ ect of the booster vaccination—
planned as part of the phase 3 trial—is likely to be 
highly informative. A booster dose can restore vaccine-
induced immunity but will not have an immediate eﬀ ect 
on immunity to blood-stage parasites. Furthermore, the 
larger sample size in the phase 3 trial will provide more 
accurate point estimates for eﬃ  cacy in the age-groups 
assessed (ie, 6–12 weeks and 5–17 months) than is 
possible in a meta-analysis of phase 2b data.
In summary, we noted signiﬁ cant variation in 
estimated vaccine eﬃ  cacy by population subgroups and 
a signiﬁ cant decline in protection against clinical 
malaria over time. One might argue that the unadjusted 
pooled estimates of eﬃ  cacy nevertheless reﬂ ect what 
was actually seen in the population tested. However, the 
unadjusted pooled eﬃ  cacy is merely a weighted mean of 
eﬃ  cacies seen in the component subgroups of the 
population and, therefore, cannot be generalised to 
other populations. For instance, if the vaccine is more 
eﬀ ective at lower transmission intensity, the pooled 
vaccine eﬃ  cacy will depend on the proportion of 
children recruited in sites at low transmission intensity. 
Predictions of public health outcomes of vaccination will 
need to take account of these variations in eﬃ  cacy by 
transmission intensity and by time since vaccination.
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